NCT05820919

Brief Summary

This study seeks to improve clinical outcomes for an important, growing, and vulnerable population-nursing home residents with Alzheimer's disease or related dementias-by testing an evidence-based intervention to improve these residents' sleep. It will also examine the implementation and sustainment of this intervention.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
456

participants targeted

Target at P75+ for not_applicable alzheimer-disease

Timeline
13mo left

Started Sep 2023

Typical duration for not_applicable alzheimer-disease

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress72%
Sep 2023May 2027

First Submitted

Initial submission to the registry

April 7, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 20, 2023

Completed
5 months until next milestone

Study Start

First participant enrolled

September 7, 2023

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 29, 2027

Expected
Last Updated

March 12, 2024

Status Verified

March 1, 2024

Enrollment Period

2.6 years

First QC Date

April 7, 2023

Last Update Submit

March 11, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Sleep (actigraph measurement)

    Total sleep time (total minutes asleep each nighttime period - 10pm to 7am)

    15 week sleep intervention period

Secondary Outcomes (5)

  • Psychotropic medication use

    15 week sleep intervention period

  • Pain treatment received

    15 week sleep intervention period

  • Pain - Resident Report

    15 week sleep intervention period

  • Pain - Staff Report

    15 week sleep intervention period

  • Activities of daily living decline

    15 week sleep intervention period

Study Arms (2)

Control (each NH acts as its own control):

OTHER

Each nursing home serves as its own control. Control data will be collected for 1 week (then the intervention will begin).

Other: No intervention (control period/baseline data collection)

Intervention (all NHs receive the intervention):

EXPERIMENTAL

The intervention arm includes a ten-week active intervention phase, then a five-week sustainment phase.

Behavioral: LOCK Sleep Program

Interventions

The LOCK sleep program is a program that trains NH staff in a NH frontline staff huddling approach. It is derived from evidence supporting strengths-based learning, systematic observation, relationship-based teamwork, and efficiency. Staff learn how to work together as a team to collaboratively problem-solving about resident sleep challenges (e.g., evidence-based sleep promoting best practices and daytime meaningful activity best practices).

Intervention (all NHs receive the intervention):

Each NH serves as its own control. During the control period, baseline data will be collected.

Control (each NH acts as its own control):

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Nursing home residents aged \>=50 years with an Alzheimer disease or related dementia (ADRD) diagnosis, identified by nursing home staff participating in frontline LOCK sleep huddles as having sleep problems

You may not qualify if:

  • Residents with a high risk of OSA who are not being treated for OSA because actigraph measurements are inaccurate in that population.
  • Residents who have a persistent bilateral resting tremor or paralysis in both arms (a subset of persons with Parkinson's disease and related significant tremor-causing diagnoses), due to actigraph measurement inaccuracies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Vivage/Beecan Corporation

Lakewood, Colorado, 80228, United States

RECRUITING

National HealthCare Corporation

Murfreesboro, Tennessee, 37130, United States

RECRUITING

Caraday Healthcare, LLC

San Marcos, Texas, 78666, United States

RECRUITING

MeSH Terms

Conditions

Alzheimer DiseaseDementiaSleep Wake DisordersParasomnias

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Lynn Snow, PhD

    The University of Alabama

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Lynn Snow, PhD

CONTACT

Brian Cox, MS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: This is a wedge- based cluster randomized, controlled trial (RCT) design with each NH acting as its own control. The unit of random assignment is the NH. There are 24 NHs - 8 from each of 3 corporations. Each NH serves as its own control. Control data are collected for 1 week, then the intervention will begin with intervention data collected for 15 weeks (10-week active intervention period, and five-week sustainment period). All NHs are assigned to the control group and then phased into the intervention group at 37-week intervals (steps). Our stepped wedge design has 4 steps with 6 NHs per step (2 NHs per corporation per step). We will randomly assign the order in which the 8 NHs within each corporation are phased into the intervention group. We will randomize NHs within corporations to steps after matching on bed size and number of long-stay residents with ADRD diagnoses.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 7, 2023

First Posted

April 20, 2023

Study Start

September 7, 2023

Primary Completion

April 1, 2026

Study Completion (Estimated)

May 29, 2027

Last Updated

March 12, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will share

We will share de-identified participant data by depositing data files and associated code books and analysis files with the data repository dataverse (dataverse.org). We will follow the University of Alabama IRB guidance and approval for ensuring that our data is appropriately de-identified before posting to dataverse. Our IRB-approved informed consent and HIPPAA forms seek participant permission for broad inclusion of participant data for these data sharing and secondary analysis purposes. We do not have authority to share Minimum Data Set (MDS) data, so we cannot deposit these data directly. However, we will share our analysis files and instructions on how to work with the federal owners of these data to request access; in this way other researchers will be able to replicate our steps in constructing the MDS data sets once they obtain the data from the federal owners (who do provide the data to the public via a standardized credentialed request process for a fee).

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Data will become available no later than 1 year after data collection is completed and will remain available for 1 year.
Access Criteria
Interested parties will be invited to submit access requests and plan for use of data. Data use plans will be reviewed for scientific merit and ethics.

Locations